# Lexicon Pharmaceuticals (LXRX) — Earnings

LXRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lxrx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.07 |
| EPS estimate | −$0.05 |
| EPS surprise | −39.44% |
| Revenue surprise | −82.66% |
| Revenue | $692,000.00 |
| Revenue estimate | $4.0M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1062822/000106282226000117/lxrx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/bb0fdd2a-ef3c-512d-582d-26563633d0c4.html) |

Lexicon Pharmaceuticals reported Q2 2026 results on August 6, 2026. It posted a loss of $0.07 per share, wider than the $0.05 loss expected, a 39.44% miss. Revenue was $692,000, well below the $4.0 million consensus. A year earlier, in Q2 2025, Lexicon earned $0.01 per share on revenue of $28.9 million, so revenue fell about 98% year over year.

Revenue in the table is small and uneven. It stayed below $1 million a quarter through 2023 and between $1.1 million and $1.8 million in the first three quarters of 2024. Since then it has swung widely, from $26.6 million in Q4 2024 and $28.9 million in Q2 2025 to $1.3 million in Q1 2025 and $692,000 in the latest quarter. The annual loss was $0.61 per share in 2022, $0.80 in 2023, $0.64 in 2024 and $0.14 in 2025. Q2 2025 was the only profitable quarter in the table. Over the last 20 quarters, Lexicon beat the EPS estimate 15 times and missed five.

Lexicon reported Q3 between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.05 | −$0.07 | -39.44% | $4.0M | $692,000.00 |
| Q1 2026 | May 7, 2026 | −$0.03 | $0.00 | 100.00% | $9.8M | $21.1M |
| Q4 2025 | Mar 5, 2026 | −$0.07 | −$0.04 | 42.03% | $3.1M | $5.5M |
| Q3 2025 | Nov 6, 2025 | −$0.07 | −$0.04 | 39.39% | $4.6M | $14.2M |
| Q2 2025 | Aug 6, 2025 | −$0.08 | $0.01 | 113.33% | $4.9M | $28.9M |
| Q1 2025 | May 13, 2025 | −$0.10 | −$0.07 | 26.32% | $1.4M | $1.3M |
| Q4 2024 | Mar 6, 2025 | −$0.13 | −$0.09 | 29.30% | $6.5M | $26.6M |
| Q3 2024 | Nov 12, 2024 | −$0.16 | −$0.18 | -10.57% | $3.0M | $1.8M |
| Q2 2024 | Aug 1, 2024 | −$0.18 | −$0.17 | 3.95% | $3.4M | $1.6M |
| Q1 2024 | May 2, 2024 | −$0.18 | −$0.20 | -11.11% | $1.4M | $1.1M |
| Q4 2023 | Mar 11, 2024 | −$0.22 | −$0.20 | 7.92% | $1.3M | $702,000.00 |
| Q3 2023 | Nov 8, 2023 | −$0.21 | −$0.21 | 2.19% | $2.1M | $162,000.00 |
| Q2 2023 | Aug 3, 2023 | −$0.17 | −$0.22 | -25.93% | $66,667.00 | $317,000.00 |
| Q1 2023 | May 2, 2023 | −$0.18 | −$0.17 | 5.19% | $33,333.00 | $24,000.00 |
| Q4 2022 | Mar 2, 2023 | −$0.13 | −$0.16 | -19.49% | $50,000.00 | $28,000.00 |
| Q3 2022 | Nov 9, 2022 | −$0.14 | −$0.13 | 7.21% | $50,000.00 | $39,000.00 |
| Q2 2022 | Aug 2, 2022 | −$0.16 | −$0.16 | 0.68% | $100,000.00 | $35,000.00 |
| Q1 2022 | May 5, 2022 | −$0.17 | −$0.16 | 3.44% | $50,000.00 | $37,000.00 |
| Q4 2021 | Feb 28, 2022 | −$0.18 | −$0.17 | 7.00% | — | $14,000.00 |
| Q3 2021 | Nov 3, 2021 | −$0.18 | −$0.16 | 9.91% | — | $23,000.00 |

## Frequently Asked Questions

### When did Lexicon Pharmaceuticals (LXRX) last report earnings?

Lexicon Pharmaceuticals last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did LXRX beat earnings estimates?

No. Lexicon Pharmaceuticals reported EPS of −$0.07 for Q2 2026 against a −$0.05 estimate — a 39.44% miss.

### How much revenue did LXRX report last quarter?

Lexicon Pharmaceuticals reported $692,000.00 in revenue for Q2 2026, against a consensus estimate of $4.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).